Curanex Pharmaceuticals Q3 2026 Results: Net Loss of $2.82M, Loss Widens
Curanex Pharmaceuticals Inc reported a net loss of $9.26 million for the nine months ended September 30, 2026, a significant increase from the $1.15 million loss in the prior year period, primarily driven by a surge in Research & Development expenses. The company's cash position decreased to $1.58 million from $4.97 million at the start of the year, reflecting ongoing operational burn as it develops botanical drugs for inflammatory diseases.
- Key figure
- Net loss $2.82M